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Abstract
Background: Results of meta-analyses of randomized trials comparing PEG and NaP are inconsistent and have not
included trials comparing either or both preps to less traditional ones.
AIM: To perform a meta-analysis by treatment arm.
Methods: Using MEDLINE and EMBASE, we identified English-language trials published from 1990 to 2008 that
included PEG and/or NaP, and aggregated them by treatment arm into: 4 liter (L) PEG; 2 L PEG; split-dose PEG; two
45 ml doses of NaP +/- adjunctive medication; and NaP tablets. We compared prep quality and the proportion
completing the prep.
Results: Among 71 trials (patient N = 10,201), excellent prep quality was present in 34% (CI, 26-41%) for 4 L PEG
alone; 39% (CI, 26-51%) for 2 L PEG; 37% (CI, 28-46%) for split-dose PEG; 42% (CI, 33-51%) for NaP solution; 44% (CI,
38-51%) for NaP with adjunctive meds; and 58% (CI, 49-67%) for NaP tablets. Patients receiving NaP were more
likely to complete the prep (97% [CI, 96-98%] vs. 90% [CI, 87-92%] for 4L PEG alone); however, completion rates for
2L PEG (98%) and split dose PEG (95%) were similar to NaP.
Conclusions: NaP tablets resulted in better prep quality and higher completion rates compared to other regimens.
In comparisons limited by sample size, split dose PEG was not statistically different from NaP solution for
completion rate or prep quality.
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Background
Colonoscopy is a well-established procedure for screen-
ing, diagnosis and treatment of colorectal disorders
[1,2]. For colonoscopy to be effective, adequate prepara-
tion of the bowel is required for visualization of the
colonic mucosa. To achieve this, a bowel preparation
should be tolerable, safe, effective and convenient. Bowel
preparation is considered to be the main obstacle for
patients undergoing colonoscopy [3]. The aversion
toward bowel preparation may be related to its taste,
fluid volume ingested, or side effects such as nausea,
bloating and vomiting.
Polyethylene glycol (PEG) (NuLYTELY, Half Lytely, and
GoLYTELY; Braintree Laboratories, Inc, Braintree, MA;
Colyte; Schwarz Pharma, Milwaukee, WI, and MoviPrep;
Salix Pharmaceutical, Inc, Morrisville, NC) and sodium
phosphate (NaP) tablets (Visicol and OsmoPrep Tablets;
Salix Pharmaceuticals, Inc, Morrisville, NC), NaP solution
(Fleet Phospho-soda; C.B. Fleet Company, Inc, Lynchburg,
VA), are the most widely used agents for colon cleansing.
Polyethylene glycol is an orally administered isotonic solu-
tion introduced in 1980 [4]. Since PEG is nondigestible
and nonabsorbable, it cleanses the colon by purging of
intraluminal contents [5]. Because it is iso-osmolar with
plasma, the large volume of PEG does not result in signifi-
cant fluid shifts. It has been shown to be highly effective
when taken as instructed (4L of PEG solution). However,
the efficacy of standard 4 L PEG outside of clinical trials is
compromised by poor patient compliance. The large
volume and taste are the main factors that contribute to
poor patient compliance and tolerability [6-8], which led
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without laxatives, sulfate-free, and flavored PEG solutions
(Half Lytely, NuLYTELY) in an attempt to reduce the sul-
fate odor and improve taste [9]. In some studies, split-dose
PEG has been more effective than standard 4L PEG
[10,11].
Sodium phosphate (NaP), a buffered saline laxative,
gained popularity as an alternative method for colonic
preparation due to its smaller volume. Containing
monobasic sodium phosphate and dibasic sodium phos-
phate, NaP acts as an osmotic laxative, cleansing the
colon by drawing fluids into the gastrointestinal tract.
Several randomized trials and meta-analyses comparing
PEG and NaP have suggested that NaP is safe, better
tolerated, cost-effective, and equally or more effective
[5,12-15]. NaP tablets (Visicol
®) were designed to
i m p r o v et h et a s t ea n dr e d u c et h ev o l u m er e q u i r e df o r
bowel preparation. NaP tablets contain microcrystalline
cellulose which can be deposited in the colon requiring
additional irrigation. A newer residue-free formulation
of sodium phosphate tablets (OsmoPrepTM) was intro-
duced [16] to overcome this limitation.
Previous meta-analyses, [5,17,18] have included head-
to-head trials of PEG vs. NaP but have not included
trials comparing either or both of these preps to other,
less commonly used preps. The objective of this meta-
analysis was to quantify and compare the effect of the
two bowel preps on efficacy of and patient adherence to
NaP vs. PEG for elective colonoscopy.
Methods
Search Strategy and selection criteria
We searched the medical literature from January 1990 to
December 2008 using MEDLINE and EMBASE biblio-
graphic databases and identified all relevant English lan-
guage publications. The search strategy used the
following MeSH terms: 1) colonoscopy, 2) polyethylene
glycol, 3) phosphates, 4) cathartics and 5) bowel prep.
We limited these sets of articles to diagnostic and thera-
peutic uses and to human studies published in English.
In addition, we hand-searched the reference lists of every
selected primary study for additional trials. The following
criteria were used to select studies for inclusion: 1) study
design: randomized controlled trial (RCT), 2) patient
population: adult patients undergoing elective colono-
scopy, 3) year of publication (1990-2008), 4) dosing and
frequency schedules of PEG and NaP commonly used in
clinical practice. We excluded duplicate trials, those that
lacked categorical data on both prep quality and adher-
ence; review articles; editorials; and letters to the editor.
Assembling the treatment arms
The analysis compared on treatment arms rather than
individual trials. Each trial was disassembled and
aggregated by treatment arm [19,20] into one of the fol-
lowing groups: 1) 4 liter PEG +/- adjunctive medications
(e.g., dulcolax), 2) 2 liter PEG, 3) Split-dose PEG, 4)
NaP solution - two 45 ml doses +/- adjunctive medica-
tions, 5) NaP tablets. Disassembly of the trials into treat-
ment arms was based on the determination that the
treatment arms were clinically homogeneous in compo-
sition. This determination was based on a qualitative
assessment of similarity of the trial populations, study
settings, prep regimens, ratings of bowel prep quality,
and outcomes. All descriptive and quantitative data
were extracted from the papers to an analytic database.
If the data for the particular variable were not available,
that variable was excluded from analysis and no
assumption was made about the missing data.
Quantitative analysis
Descriptive data were extracted to determine clinical
similarity of the individual trials; extracted quantitative
data included the number of subjects in each treatment
arms and those with each outcome. Discrepancies in
data extraction were resolved in discussion. For pooling
procedures, the extracted data were combined across
treatment arms rather than across individual trials. We
assumed the presence of clinical heterogeneity because
of variation in factors that were not consistently
described in each trial, such as prep timing, consump-
tion of additional liquids, and dietary instructions. We
combined the data using the random effects model
developed by DerSimonian-Laird [21], which adjusts for
variation within treatment arms and provides a more
conservative estimate an effect by providing wider confi-
dence intervals (CIs). We compared prep quality (excel-
lent, good, fair, poor) and the percent of persons
completing the prep using weighted, summary- level
proportions and 95% CI. All analyses and calculations
were done using r-meta library (version 2.14) for the
statistical software R (version 2.5.1).
Results
Descriptive findings
One hundred seventy four abstracts were obtained from
1990 through 2008 using MEDLINE and EMBASE; 50
were excluded as they were either published prior to
1990 (n = 18), involved bowel preparation for non colo-
noscopy use (n = 11), were published in foreign lan-
guage (n = 8), or were non-randomized controlled trials
(n = 13). Of the 124 randomized controlled trials
included for full text review, 53 trials were excluded.
The number of articles and reasons for exclusion were
as follows: trials which included a pediatric population
(n = 6); trials that did not include PEG or NaP (n = 24);
trials with no categorical data (n = 12); and trials with
non-traditional doses of either prep (e.g., single dose 3L
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or 90 mL; n = 11) were excluded (Figure 1).
For analysis, we included 71 randomized controlled
trials [6-8,10-14,16,22-83] involving 10,201 patients.
Trial aggregation by treatment arm resulted in the fol-
lowing prep arms: 4 liter PEG with and without adjunc-
tive medications (e.g., metoclopramide, dulcolax); 2 liter
PEG; split-dose PEG; NaP solution - two 45 ml doses
with and without adjunctive medications; and NaP
tablets. All low volume PEG trials (i.e., 2 liter) invariably
used an adjunctive medication such as bisacodyl (70%),
senna (20%), and magnesium citrate or ascorbic acid
(10%). Trials that used split dose PEG regimen either
divided a 4 liter dose into 2 liter the day before and 2
liter on the day of the procedure or divided a 3 liter
dose into 2 liter the day before and 1 liter the day of the
procedure.
Descriptive data for each treatment arm is shown in
Table 1. Overall mean age was 58 years; 49% of the
study participants were men. At least 68 (95.7%) of 71
trials were investigator-blinded. The trials had compar-
able study populations; individual trial inclusion criteria
consisted of patients with indications for screening or
diagnostic colonoscopy. Exclusion criteria generally
included congestive heart failure, recent myocardial
infarction, renal insufficiency, and cirrhosis with ascites.
All trials used comparable scales for rating bowel prep
quality [6]: excellent prep quality was defined as a small
volume of clear liquid or greater than 95% of surface
seen; good prep quality was defined as large volume of
clear liquid covering 5% to 25% of the surface but
greater than 90% of surface seen; fair prep quality was
defined as some semi-solid stool that could be suctioned
or washed away but greater than 90% of surface seen;
and poor prep quality was defined as: semi-solid stool
t h a tc o u l dn o tb es u c t i o n e do rw a s h e da w a ya n dl e s s
than 90% of the surface seen. A few trials defined prep
quality as “excellent or good”, satisfactory (excellent or
good), or unsatisfactory (fair or poor). These definitions
were comparable to the individual quality components
of the four point scale for prep quality [6].
The method of preparation of PEG and NaP were
similar among the trials with some variation in the tim-
ing of prep consumption. Dietary recommendations the
day before colonoscopy varied from regular to a clear
liquid diet for lunch to a full clear liquid diet in the eve-
ning. Co-interventions accompanying trials with 2 liter
PEG, 4 liter PEG with adjunctive medications, and NaP
solution with adjunctive medications were either taken
separately and only rarely in combination with the study
preparation, and included magnesium citrate, metoclo-
pramide, psyllium, bisacodyl, cisapride, ascorbic acid,
senna, and simethicone.
Quantitative findings
The proportion of persons with excellent prep quality
were 42.1% (CI, 33-51%) for NaP solution alone; 44.4%
(CI, 38-51%) for NaP with adjunctive meds; 58.2% (CI,
49-67%) for NaP tablets; 33.7% (CI, 26-41%) for 4 liter
PEG alone; 38.7% (CI, 26-51%) for 2 literL PEG; and
37.2% (CI, 28-46%) for split-dose PEG (Table 2). Based
on the criterion of minimal or no overlap of the 95%
CIs, NaP tablets resulted in a greater likelihood of
achieving an excellent quality prep than did all PEG
groups, while NaP solution was intermediate. All PEG
groups were essentially equivalent with respect to prep
quality (Table 2).
The composite measure of excellent or good quality
preparation was achieved by 76.3% (CI, 72-81%) of those
who used NaP solution alone; by 68.7% (CI, 54-84%) of
those who used NaP solution with adjunctive medica-
tion; and by 87.8% (CI, 83-93%) of those who used NaP
tablets (Table 3 and Figure 2). For the PEG treatment
subgroups, an excellent or good prep quality was
achieved by 71.5% (CI, 64-80%) for 4 liter PEG alone; in
67.8% (CI, 49-87%) for 4 liter PEG with adjunctive med-
ications; in 69.2% (CI, 58-81%) for 2 liter PEG; and in
66.4% (CI, 31-100%) for split-dose PEG. Use of NaP
tablets was more likely to result in good or excellent
quality prep than both NaP solution groups. When
compared to the PEG groups, NaP tablets were superior
to both 4 liter and 2 liter PEG groups and were superior
to 4 liter PEG with adjunctive medications, with mini-
mally overlapping CIs. All comparisons that included
split-dose PEG resulted in significant overlap of the 95%
CIs because of both the relatively small numbers of sub-
jects in this group and the variation in results among
the individual studies. Thus, while split-dose PEG was
not statistically different from any of the other groups,
the proportion of subjects with a good or excellent
                             
124 randomized controlled 
trials for full text review
174 relevant abstracts for 
assessment
50 studies excluded: (<1990, non 
colonoscopy, non RCTs ; and 
foreign language)
53 studies excluded: (pediatrics, 
non PEG or non- NaP, studies 
with no categorical data and 
studies using nontraditional 
dosing)
71 studies included for final 
analysis 
Figure 1 Flow chart diagram for the studies identified in the
meta-analysis.
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to a clinically-important degree as compared with NaP
tablets.
Prep completion rates are shown in Table 3 and Fig-
ure 3. Patients who received NaP either alone in liquid
form or in tablet form were more likely to complete the
prep (97.3% [CI, 96-98%] and 97.2% [CI, 95-99] respec-
tively, vs. 89.5% [CI, 87-92%] for PEG). However, com-
pletion rates for 2L PEG (98%) and split-dose PEG
(95%) were similar to NaP.
Discussion
This meta-analysis examined 71 randomized controlled
trials that included NaP or PEG solution or both for
bowel preparation prior to elective, outpatient colono-
scopy. The findings indicate that NaP resulted in an
excellent quality prep more often than PEG. Further,
based on minimal or no overlap of the 95% CIs, NaP
tablets resulted in a greater likelihood of achieving an
excellent quality prep than did all PEG groups, while
NaP solution was in between. There was no difference
in prep quality among the various PEG subgroups.
Among treatments arms where prep quality could be
quantified as a composite of excellent or good, NaP
tablets (87.8%) were numerically superior to all other
forms of either prep. There was minimal overlap of the
95% CI of NaP tablets with those of both NaP solution
and 4 L PEG arms, both of which included adjunctive
medications. Despite an absolute difference of just over
21% between NaP tablets and split dose 4 L PEG that
favored NaP tablets, the CIs showed a large degree of
overlap, most likely due to the imprecision of the indivi-
dual trial point estimate for split dose PEG. Finally,
among the trials that included completion rates, NaP
was more likely to be completed than PEG, with the
exception of the split dose PEG regimen.
Previous meta-analyses of head-to-head trials of PEG
vs. NaP have reported that sodium phosphate is more
effective, better tolerated, and less costly than PEG
[5,18]. However, in 2007 a meta-analysis by Belsey et al
reported that no single bowel preparation was consis-
tently superior to others [17]. Both meta-analyses
excluded data from trials comparing either or both of
these preps to other, less commonly used preps.
This analysis has strengths and limitations. One
strength is the breadth of our search strategy and analy-
sis, as we included studies that have been excluded in
other systematic reviews. Another strength is the clinical
homogeneity of the patient population studied: all
groups were comprised of outpatients undergoing elec-
tive colonoscopy. Further, as best we could determine,
the study populations, even after re-assembly by treat-
ment arm, appear to be demographically and clinically
comparable. Finally, the large sample size of this analysis
provides reasonable precision for most of the point esti-
mates of effect for both efficacy and tolerability.
With regard to limitations, the potential for clinical
heterogeneity is always present when combining trials,
particularly for factors that were not measured. The
possibility of clinical heterogeneity appears to be low; to
minimize its effects, we used a random effects model,
which accounts for heterogeneity by both providing a
p o i n te s t i m a t et h a ti sl e s sw e i g h t e db yt h es t u d i e sw i t h
larger sample sizes and resulting in wider confidence
intervals. Several candidate factors may contribute to
clinical and/or methodological heterogeneity among
Table 1 Descriptive data for each prep treatment arm
Prep Treatment Arm # of Treatment Arms # of Pts Mean Age, y (range) % Males (range)
NaP Solution alone 31 2463 58.2 (51-84) 46.6 (20-77)
NaP Solution with adjunctive meds 5 358 56.3 (52-60) 44.6 (31-52)
NaP Tablets 7 1793 56.3 (56-58) 43.7 (40-49)
4L PEG alone 33 2729 59.3 (52-84) 48.2 (14-99)
4L PEG with adjunctive meds 6 372 63.3 (58-81) 57.9 (34-100)
2L PEG 17 1919 58.6 (54-62) 52.6 (30-99)
Split dose PEG 5 567 55.3 (52-57) 49.6 (37-65)
Table 2 Prep quality by treatment arm
Prep Treatment Arm # of Treatment Arms % Excellent (95% CI) % Good (95% CI) % Fair (95% CI) % Poor (95% CI)
NaP Solution alone 22 42.1 (33-51) 31.0 (25-37) 16.4 (13-20) 7.0 (5-9)
NaP Sol’n with adjunctive meds 3 44.4 (38-51) 23.0 (18-28) 26.2 (21-32) 5.6 (2-9)
NaP tablets 7 58.2 (49-67) 28.8 (22-36) 9.9 (7-14) 1.4 (0.6-2)
4L PEG alone 23 33.7 (26-41) 36.8 (33-41) 23.3 (15-31) 5.9 (4-8)
2L PEG 11 38.7 (26-51) 38.6 (29-48) 23.5 (13-34) 4.3 (2-6)
Split dose PEG 5 37.2 (28-46) 43.0 (35-51) 11.1 (5-17) 5.7 (1-10)
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Page 4 of 10trials. One factor is variation in timing of bowel prep.
T h et i m ea tw h i c ht h eb o w e lp r e pw a ss t a r t e dw a sn o t
uniform among the trials ranging from 2:00 PM in the
afternoon to 7:00 PM in the evening the day before the
scheduled procedure. This may have affected those
patients undergoing colonoscopy in the afternoon by
affecting prep quality particularly in the right colon,
where intestinal chyme can accumulate, obscuring the
mucosa. Another factor potentially contributing to het-
erogeneity is the variation in dietary instructions prior
to and during the prep, which also were not uniform
among the trials, and which ra n g e df r o mar e g u l a rd i e t
to a clear liquid diet for lunch and clear liquid diet in
the evening.
A second limitation is the uncertain acceptability of
the “treatment-arm” method of doing meta-analysis.
While this method has been used previously for com-
paring treatments for rheumatoid arthritis [19], for
prevention of deep venous thrombosis following total
hip replacement [84] and for treatment of premature
Table 3 Prep quality (Excellent/Good) and completion rates by treatment arm
Prep Treatment Arm # of Treatment Arms # of Pts % Good or Excellent (95% CI) % Prep Completed (95% CI)
NaP Solution alone 31 2463 76.3 (72-81) 97.3 (96-98)
NaP Sol’n with adjunctive meds 5 358 68.7 (54-84) 92.9 (85-99)
NaP Tablets 7 1793 87.8 (83-93) 97.2 (95-99)
4L PEG alone 33 2729 71.5 (64-80) 89.5 (87-92)
4L PEG with adjunctive meds 6 372 67.8 (49-87) 95.3 (86-100)
2L PEG 17 1919 69.2 (58-81) 98.0 (96-100)
Split dose PEG 5 567 66.4 (31-100) 95.4 (86-100)
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Figure 2 Forest plot of preparation quality by treatment arm.
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Page 5 of 10labor [85], its validity is less well established than is
head-to-head meta-analysis where comparators are the
same in all studies. Limiting the analysis to a head-to-
head comparison would not have allowed considera-
tion of evidence from trials where either NaP or PEG
was compared to another bowel preparation. An alter-
native to our “treatment-arm” approach is a mixed
treatment comparison or “network” meta-analysis,
which is another way of quantitatively aggregating data
across studies containing disparate comparators
[86,87]. It allows comparison of multiple treatments,
combining direct and indirect evidence in a single ana-
lysis. While head-to-head meta-analysis and network
meta-analysis of the same data have been compared
[88], there are no comparative analyses between net-
work and treatment-arm meta-analyses. In the absence
of such comparative data, it remains uncertain which
method is most appropriate for synthesizing quantita-
tive data, and under which circumstances the two
methods differ in results.
A third potential factor is the variation in definitions
of patient tolerance of the prep. While some trials
defined patient tolerance by different parameters (e.g.
completion rates, willingness to repeat the prep, palat-
ability and adverse affects), others defined patient toler-
ance as a single parameter and reported it as a single
cumulative estimate.
In recent years, three reports have described 22
patients who developed renal insufficiency due to
nephrocalcinosis that was temporally associated with use
of NaP for colonoscopy prep, 4 of whom progressed to
end stage renal disease requiring dialysis [89-91]. The
majority of these patients had co-morbid conditions
such as diabetes mellitus, hypertension (treated with
angiotensin-converting enzyme inhibitors [ACE-I] or
angiotensin receptor blockers [ARBs] or diuretics), pre-
existing renal insufficiency, were elderly, or had small
bowel disease that resulted in calcium and vitamin D
malabsorption. Renal biopsies of many of the cases
showed nephrocalcinosis with intra-tubular deposition
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Page 6 of 10of calcium-phosphate. The term for this pathologic con-
dition is acute phosphate nephropathy (APN). The his-
topathology suggests that sodium phosphate ingestion
leads to obstructive calcium-phosphate crystalluria fol-
lowed by acute intra-tubular nephrocalcinosis. These
reports have recently raised concerns that led Food and
Drug Administration [92] to announce a safety alert in
December 2008, stating that a boxed warning would be
added to the labeling on prescription OSPs (Visicol and
OsmoPrep) and recommending against use of over-the-
counter OSPs for bowel preparation. Shortly after this
announcement, all over-the-counter NaP products were
voluntarily removed from the market, with a subsequent
sharp decline in use of NaP solution.
Despite the FDA’s action and resulting reaction, the
published data suggest that absolute risk of APN is very
low [93,94]. Further, a recent systematic review and
meta-analysis of seven controlled studies (patient N =
14,520) of the effects of NaP versus comparator on kid-
ney function showed that there is significant clinical het-
erogeneity in the populations studied, study methods,
definition of kidney injury, and results [95]. Quantita-
tively, the pooled odds ratio for kidney injury among
NaP-treated patients ranged from 1.08 (CI, 0.71-1.62) to
1.22 (CI, 0.77-1.92). The investigators concluded that it
was not possible to discern whether there is a true asso-
ciation between NaP and kidney injury.
The results of this meta-analysis apply to patients
undergoing elective colonoscopy who do not have a
history of co-morbid conditions such as renal insuffi-
ciency, recent myocardial infarction, ascites due to cir-
rhosis, and congestive heart failure. Further, NaP
should not be used by patients with suspected or
established inflammatory bowel diseases because of
aphthous ulcerations it may cause [96]. While NaP
solution is not currently available, tablet forms of NaP
remain available by prescription only. Physicians
should be aware of the risk of acute kidney injury with
NaP preparations and should not use it in older
patients, in those with preexisting renal insufficiency,
and in patients on medications that can affect volume
status or renal function (diuretics, ACE inhibitors, and
ARBs). Further, all patients should be encouraged to
adequately hydrate themselves prior to and while using
NaP preparations.
Conclusions
In conclusion, this treatment-arm meta-analysis of NaP
and PEG suggests that NaP tablets result in a better
quality prep than NaP solution, 2L PEG, and 4 L PEG
alone. NaP is more likely to be completed overall. In
comparisons limited by sample size, split dose PEG was
not statistically different from NaP for both completion
rate and prep quality. Head-to-head trials between split-
dose PEG and NaP tablets would be useful in further
defining the relative efficacy of these two regimens.
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